Skip to main content
PMC home page
Heart logoLink to Heart
. 1999 Aug;82(2):170–175. doi: 10.1136/hrt.82.2.170

An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation

R Steeds 1, A Birchall 1, M Smith 1, K Channer 1
PMCID: PMC1729147  PMID: 10409530

Abstract

OBJECTIVE—To compare sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation.
DESIGN—Prospective, randomised, open label, crossover study.
SETTING—University hospital.
PATIENTS—47 subjects aged over 50 years were recruited from the hospital outpatient department following ECG documentation of paroxysmal atrial fibrillation that coincided with symptoms. Six patients withdrew and 41 completed the trial.
INTERVENTIONS—Patients were randomised to one month's treatment with sotalol 80 mg twice daily or atenolol 50 mg once daily. Treatment arms were then crossed over. Patients underwent 72 hour Holter monitoring before randomisation and repeat studies were carried out at the end of both treatment periods. Symptom assessments were completed using linear analogue scales and the Nottingham health profile.
MAIN OUTCOME MEASURE—Frequency of paroxysmal atrial fibrillation; secondary outcome measures included average and total duration of paroxysmal atrial fibrillation, total ectopic count, and symptom assessments.
RESULTS—A reduction in the number and duration of episodes of paroxysmal atrial fibrillation was noted following treatment with sotalol and atenolol. There was no difference in frequency of paroxysmal atrial fibrillation during treatment with sotalol or atenolol (median difference 0; 95% confidence interval (CI) 0 to 1; p = 0.47). There was no difference in total duration of paroxysmal atrial fibrillation (median difference 0 min; 95% CI −1 to 2; p = 0.51) or in average duration (median difference 0 min; 95% CI 0 to 1; p = 0.31). No difference was found in total ectopic count between sotalol and atenolol (median difference −123; 95% CI −362 to 135; p = 0.14). Treatments were equally tolerated with no difference in linear analogue scores for symptoms of paroxysmal atrial fibrillation (median difference −5; 95% CI −20 to 5; p = 0.26) or in all categories of the Nottingham health profile.
CONCLUSIONS—No difference was found in terms of ECG or symptomatic control of paroxysmal atrial fibrillation between prescribing sotalol 80 mg twice daily and atenolol 50 mg once daily. There was an improvement in paroxysmal atrial fibrillation from baseline following treatment with either sotalol or atenolol.


Keywords: paroxysmal atrial fibrillation; sotalol; atenolol

Full Text

The Full Text of this article is available as a PDF (106.2 KB).

Figure 1  .

Figure 1  

Open in a new tab

Frequency of paroxysmal atrial fibrillation for each period of ECG monitoring.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Channer K. S., Jones J. V. Atrial systole: its role in normal and diseased hearts. Clin Sci (Lond) 1988 Jul;75(1):1–4. doi: 10.1042/cs0750001. [DOI] [PubMed] [Google Scholar]
  2. Channer K. S. The drug treatment of atrial fibrillation. Br J Clin Pharmacol. 1991 Sep;32(3):267–273. doi: 10.1111/j.1365-2125.1991.tb03898.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Echt D. S., Berte L. E., Clusin W. T., Samuelsson R. G., Harrison D. C., Mason J. W. Prolongation of the human cardiac monophasic action potential by sotalol. Am J Cardiol. 1982 Nov;50(5):1082–1086. doi: 10.1016/0002-9149(82)90421-0. [DOI] [PubMed] [Google Scholar]
  4. Echt D. S., Liebson P. R., Mitchell L. B., Peters R. W., Obias-Manno D., Barker A. H., Arensberg D., Baker A., Friedman L., Greene H. L. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781–788. doi: 10.1056/NEJM199103213241201. [DOI] [PubMed] [Google Scholar]
  5. Edvardsson N., Hirsch I., Emanuelsson H., Pontén J., Olsson S. B. Sotalol-induced delayed ventricular repolarization in man. Eur Heart J. 1980 Oct;1(5):335–343. doi: 10.1093/eurheartj/1.5.335. [DOI] [PubMed] [Google Scholar]
  6. Hindman N., Grande P., Harrell F. E., Jr, Anderson C., Harrison D., Ideker R. E., Selvester R. H., Wagner G. S. Relation between electrocardiographic and enzymatic methods of estimating acute myocardial infarct size. Am J Cardiol. 1986 Jul 1;58(1):31–35. doi: 10.1016/0002-9149(86)90236-5. [DOI] [PubMed] [Google Scholar]
  7. Janssen J., Loomans L., Harink J., Taams M., Brunninkhuis L., van der Starre P., Kootstra G. Prevention and treatment of supraventricular tachycardia shortly after coronary artery bypass grafting: a randomized open trial. Angiology. 1986 Aug;37(8):601–609. doi: 10.1177/000331978603700807. [DOI] [PubMed] [Google Scholar]
  8. Juul-Möller S., Edvardsson N., Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990 Dec;82(6):1932–1939. doi: 10.1161/01.cir.82.6.1932. [DOI] [PubMed] [Google Scholar]
  9. Kannel W. B., Abbott R. D., Savage D. D., McNamara P. M. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J. 1983 Aug;106(2):389–396. doi: 10.1016/0002-8703(83)90208-9. [DOI] [PubMed] [Google Scholar]
  10. Lamb R. K., Prabhakar G., Thorpe J. A., Smith S., Norton R., Dyde J. A. The use of atenolol in the prevention of supraventricular arrhythmias following coronary artery surgery. Eur Heart J. 1988 Jan;9(1):32–36. [PubMed] [Google Scholar]
  11. Lip G. Y., Metcalfe M. J., Rae A. P. Management of paroxysmal atrial fibrillation. Q J Med. 1993 Aug;86(8):467–472. doi: 10.1093/qjmed/86.8.467. [DOI] [PubMed] [Google Scholar]
  12. Mangano D. T., Layug E. L., Wallace A., Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med. 1996 Dec 5;335(23):1713–1720. doi: 10.1056/NEJM199612053352301. [DOI] [PubMed] [Google Scholar]
  13. Mason J. W. Amiodarone. N Engl J Med. 1987 Feb 19;316(8):455–466. doi: 10.1056/NEJM198702193160807. [DOI] [PubMed] [Google Scholar]
  14. Ommen S. R., Odell J. A., Stanton M. S. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med. 1997 May 15;336(20):1429–1434. doi: 10.1056/NEJM199705153362006. [DOI] [PubMed] [Google Scholar]
  15. Suttorp M. J., Kingma J. H., Peels H. O., Koomen E. M., Tijssen J. G., van Hemel N. M., Defauw J. A., Ernst S. M. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol. 1991 Nov 1;68(11):1163–1169. doi: 10.1016/0002-9149(91)90188-q. [DOI] [PubMed] [Google Scholar]
  16. Suttorp M. J., Kingma J. H., Tjon Joe Gin R. M., van Hemel N. M., Koomen E. M., Defauw J. A., Adan A. J., Ernst S. M. Efficacy and safety of low- and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations. J Thorac Cardiovasc Surg. 1990 Dec;100(6):921–926. [PubMed] [Google Scholar]
  17. Takahashi N., Seki A., Imataka K., Fujii J. Clinical features of paroxysmal atrial fibrillation. An observation of 94 patients. Jpn Heart J. 1981 Mar;22(2):143–149. doi: 10.1536/ihj.22.143. [DOI] [PubMed] [Google Scholar]
  18. Touboul P., Atallah G., Kirkorian G., Lamaud M., Moleur P. Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties. Am Heart J. 1984 May;107(5 Pt 1):888–895. doi: 10.1016/0002-8703(84)90823-8. [DOI] [PubMed] [Google Scholar]
  19. Wang T., Bergstrand R. H., Thompson K. A., Siddoway L. A., Duff H. J., Woosley R. L., Roden D. M. Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol. 1986 May 1;57(13):1160–1165. doi: 10.1016/0002-9149(86)90692-2. [DOI] [PubMed] [Google Scholar]
  20. Wanless R. S., Anderson K., Joy M., Joseph S. P. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997 Apr;133(4):441–446. doi: 10.1016/s0002-8703(97)70186-8. [DOI] [PubMed] [Google Scholar]
  21. Wolk R., Kulakowski P., Karczmarewicz S., Karpinski G., Makowska E., Czepiel A., Ceremuzynski L. The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. Int J Cardiol. 1996 Jun;54(3):207–211. doi: 10.1016/0167-5273(96)02631-9. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES